TARA
Protara Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jan 7 Piper Sandler initiates
- Mar 4 JP Morgan initiates
- Mar 10 ▲ Protara Therapeutics reported strong interim clinical data for TARA-…
- Apr 1 to Apr 8 ▼ 2 days of insider sells: $125.0K by 1 insider, avg $5.27
- May 15 ▲ Protara Therapeutics announced positive updated 12-month data from i…
- May 15 FDA: Protara Therapeutics Announces Positive Updated 12-Month D…
- Jun 29 ▼ 1 insider sell $882.2K at $4.09
- Sep 30 ▼ Short interest jumps 31.1% to 5.79M
- Oct 15 FDA: Protara Therapeutics Completes Enrollment of the Phase 2b…
- Oct 30 ▲ Short interest falls 46.9% to 3.24M
- Nov 6 ▲ Earnings: TARA Q3 2026 Earnings: EPS $-0.35 (+6.2% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
2 insiders sold $1.0M.
- InstitutionsMIXED
Q3 2026: 15 added (0 new), 13 trimmed or exited.
- Short sellersCOVERING
Short interest −46.9% to 3.24M shares. 2.9 days to cover, ≈5.3% of shares.
- TrendDOWNTREND
17% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MARSHALL WACE, LLP | DOUBLED | $4.7M |
| Walleye Capital LLC | ADD | $2.8M |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | $1.6M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | TRIM | $1.1M |
| MORGAN STANLEY | TRIM | $643.6K |
| Fisher Asset Management, LLC | ADD | $395.3K |
| ALPS ADVISORS INC | ADD | $237.1K |
| Squarepoint Ops LLC | DOUBLED | $209.5K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action May 2026Price is below the lowest target. Median implies +992%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| May 20, 2026 | Oppenheimer MAINTAIN | Outperform |
| May 14, 2026 | JP Morgan MAINTAIN | Overweight |
| Apr 29, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Mar 4, 2026 | JP Morgan INITIATE | Overweight |
| Feb 10, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Jan 7, 2026 | Piper Sandler INITIATE | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Shefferman Jesse CEO and President Jun 30, 2026 | GIFT | 14,000 sh |
Shefferman Jesse CEO and President Jun 30, 2026 | GIFT | 7,000 sh |
Shefferman Jesse CEO and President Jun 30, 2026 | GIFT | 4,000 sh |
Shefferman Jesse CEO and President Jun 30, 2026 | GIFT | 5,000 sh |
Shefferman Jesse CEO and President Jun 29, 2026 | EXERCISE | $412.0K |
Shefferman Jesse CEO and President Jun 29, 2026 | SELL | $882.2K |
BESHAR LUKE M Director Jun 15, 2026 | AWARD | 31,000 sh |
GARCEAU ROGER Director Jun 15, 2026 | AWARD | 31,000 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | -$0.44 | -$0.46–-$0.42 | -1.5% | $0.00 |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
10 filings · 3 press releases · 0 bullish · 2 bearish · 8 neutral- BEARISH SC 13G/ANov 16, 2026
Janus Henderson Group Ltd. filed an amended Schedule 13G reporting 0% beneficial ownership of Protara Therapeutics as of September 30, 2026, down from prior filings. The filing indicates Janus Henderson's managed portfolios no longer hold a reportable stake in TARA, representing a full exit by a…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 8-KNov 6, 2026
Protara Therapeutics reported Q3 2026 results: net loss of $21.7M ($0.35 per share) vs $13.3M loss…
Monitor the completion of ADVANCED-2 enrollment by year-end 2026 and the interim THRIVE-3 results expected in Q4 2026, as these are key catalysts for TARA-002 and IV Choline Chloride programs. The…
- NEUTRAL PRESS-RELEASENov 6, 2026
Protara Therapeutics reported a Q3 2026 net loss of $21.7M ($0.35 per share), wider than the…
Watch for enrollment completion of the BCG-Unresponsive NMIBC cohort by year-end and interim THRIVE-3 Phase 2b results, both catalysts for TARA-002 and IV Choline Chloride programs. The in-sourcing…
- NEUTRAL PRESS RELEASEOct 15, 2026
Protara Therapeutics completed enrollment of the Phase 2b dose confirmation cohort (24 patients)…
No new data released, this is a timeline update. The key catalyst remains the interim Phase 2b data readout in 4Q 2026. Monitor for any data disclosures or regulatory interactions before that date.
All TARA filing & press-release reports (13)
- SC 13G/A reportNov 16, 2026
- 8-K reportNov 6, 2026
- PRESS-RELEASE reportNov 6, 2026
- PRESS-RELEASE reportOct 15, 2026
- PRESS-RELEASE reportAug 11, 2026
- 8-K reportAug 11, 2026
- 8-K reportJun 29, 2026
- EFFECT reportMay 26, 2026
- PRESS-RELEASE reportMay 15, 2026
- 8-K reportMay 13, 2026
- PRESS-RELEASE reportMay 13, 2026
- DEFA14A reportApr 28, 2026
- PRESS-RELEASE reportMar 10, 2026